The role of surface molecule CD229 in Multiple Myeloma. Clin Immunol 2019 Jul;204:69-73
Date
10/17/2018Pubmed ID
30326256DOI
10.1016/j.clim.2018.10.006Scopus ID
2-s2.0-85055712528 (requires institutional sign-in at Scopus site) 9 CitationsAbstract
The outcome of Multiple Myeloma (MM) patients has dramatically improved, however, most patients will still succumb to their disease. Additional therapeutic options are urgently needed and novel immunotherapies are enormously promising in the therapeutic armamentarium against MM. The first step in the development of any immunotherapy needs to be the identification of an appropriate target structure. In this review we present the current knowledge on surface molecule CD229, a member of the Signaling Lymphocyte Activation (SLAM) family of immune receptors. We believe that based on its characteristics, including (1) strong and homogenous expression on all myeloma cells, (2) expression on myeloma precursors, (3) absence from most normal tissues, (4) a central function in the biology of MM, CD229 (SLAMF3) represents a promising target for anti-MM immunotherapies. The introduction of novel anti-CD229 approaches into the clinic will hopefully lead to more durable responses, or maybe even cures, in MM.
Author List
Olson M, Radhakrishnan SV, Luetkens T, Atanackovic DAuthor
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsHumans
Multiple Myeloma
Signaling Lymphocytic Activation Molecule Family
